title: Myasthenia gravis: newer therapies offer sustained improvement.
abstract: Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.
authors.affiliation: Department of Neurology, Neuromuscular Center, Neurological Institute, Cleveland Clinic.
authors.forename: Yuebing
authors.initials: Y
authors.lastname: Li
authors.forename: Yeeshu
authors.initials: Y
authors.lastname: Arora
authors.forename: Kerry
authors.initials: K
authors.lastname: Levin
mesh_terms: D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D009157:Myasthenia Gravis / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods* / Q000639:trends